Safety and Dose Finding Study Based on the Effects of Three Subcutaneous Injections of BM32, a Recombinant Hypoallergenic Grass Pollen Vaccine, on Responses to Allergen Challenge by Skin Testing and in the Vienna Challenge Chamber (VCC) as Well as Immunological Response in Subjects Know to Suffer From Grass-pollen Induced Allergic Rhinitis.

Trial Profile

Safety and Dose Finding Study Based on the Effects of Three Subcutaneous Injections of BM32, a Recombinant Hypoallergenic Grass Pollen Vaccine, on Responses to Allergen Challenge by Skin Testing and in the Vienna Challenge Chamber (VCC) as Well as Immunological Response in Subjects Know to Suffer From Grass-pollen Induced Allergic Rhinitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2013

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Apr 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2011-003368-64).
    • 26 Apr 2012 Planned number of patients changed from 60 to 72 as reported by European Clinical Trials Database.
    • 07 Feb 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top